Member News

Hall named Vallee professor; Beverley receives endowed chair

ASBMB Today Staff
Sept. 27, 2021

Hall awarded Vallee visiting professorship

Michael Hall, a professor at the University of Basel's Biozentrum, was appointed as one of three Vallee visiting professors this year.

Michael Hall

Hall studies cell growth and target of rapamycin, or TOR, signaling. He discovered the TOR kinase in yeast in the 1990s and has since been a leader in the field that has grown in describing the kinase's key role in adjusting growth and metabolism in response to nutrient availability. TOR and its mammalian homolog, mTOR, integrate signals about a cell’s nutrient reserves and phosphorylate substrates involved in protein synthesis, ribosome production and cell growth. Hall’s lab discovered that TOR belongs to two protein complexes termed TORC1 and TORC2, which have different rapamycin sensitivity and, later research showed, signaling activity.

Born in Puerto Rico, Hall grew up in Venezuela and Peru, then moved to the continental U.S. to pursue his studies. He earned his Ph.D. from Harvard University and completed postdoctoral fellowships at the Pasteur Institute in Paris and the University of California, San Francisco. He joined the Biozentrum at the University of Basel in 1987. In 1995, he started the first of three three-year terms as chair of the university’s division of biochemistry; he also served for nine nonconsecutive years as the vice director of the Biochentrum.

Hall is a member of the National Academy of Sciences, a recipient of the Breakthrough Prize in Life Sciences, the Gairdner Award for Biomedical Research and the Albert Lasker Award for Basic Medical Research. In addition to his many awards and honors, he serves on the scientific advisory boards of several pharmaceutical companies and the editorial boards of numerous journals.

Vallee visiting professorships are sponsored by the Vallee Foundation, a private funder designed “to promote a collegial community of international scientists” and advance research. Bert and Natalie Vallee, a Harvard professor of medicine and a Lesley College professor of biology, respectively, started the foundation in 1996 to bring visiting scholars to Bert's crystallography lab. Today, Vallee visiting professors receive a $25,000 honorarium and take a one-month sabbatical at a research institution anywhere in the world. Past recipients who belong to the American Socitey for Biochemistry and Molecular Biology include Lewis Cantley, Emmanuelle Charpentier and Elaine Fuchs.

Beverley receives endowed chair

Stephen Beverley, a professor at Washington University School of Medicine and former head of the school’s department of molecular microbiology, is now a distinguished professor in that department. The new chair was named for the late Ernest St. John Simms, a WUSM professor who did groundbreaking research in genetics and immunology. 

Stephen Beverley

Beverley earned his bachelor's degree at the California Institute of Technology and a doctorate at the University of California, Berkeley. As a postdoc at Stanford, he began to study gene amplification in Leishmania, a protozoan parasite transmitted by sand flies that can attack either the skin or internal organs including the spleen and liver.

When he was an early-career professor at Harvard, Beverley developed genetic tools for studying Leishmania and collaborated on studies of its surface glycoconjugates, important virulence factors and potential vaccine targets. He moved to Washington University in St. Louis to head its department of molecular microbiology in 1997 and served in that capacity until 2018. He also directed the university’s Center for Infectious Disease Research.

Beverley co-founded a company, Symbiontics, that aimed to treat lysosomal storage diseases using biotechnological tools borrowed from Leishmania, which make their homes within the lysosome. The company was bought by BioMarin in 2010 and renamed Zystor.

These days Beverley’s lab balances research on Leishmania reproduction, biology and genetics with studies of how the parasite interacts with the human immune system. They also have a line of inquiry into how endogenous viruses lead to increased virulence.

A former member of the editorial board of the Journal of Biological Chemistry, Beverley is a member of the National Academy of Science and a fellow of the American Association for the Advancement of Science, American Academy of Microbiology and American Society of Tropical Medicine and Hygiene. He received the Peter Raven Lifetime Achievement Award from the St. Louis Academy of Sciences in 2017.

 

 

 

 

 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

In memoriam: Ralph G. Yount
In Memoriam

In memoriam: Ralph G. Yount

July 28, 2025

He was a professor emeritus of chemistry and biochemistry at Washington State University and an ASBMB member for 58 years.

From dust to discovery
Profile

From dust to discovery

July 23, 2025

From makeshift classrooms in Uganda to postdoctoral research in Chicago, MOSAIC scholar Elizabeth Kaweesa builds a legacy in women’s health.

Fliesler wins scientific and ethical awards
Member News

Fliesler wins scientific and ethical awards

July 21, 2025

He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

ASBMB members recognized as Allen investigators
Member News

ASBMB members recognized as Allen investigators

July 14, 2025

Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.